Everolimus and Octreotide LAR in Neuroendocrine Tumors: An I.T.M.O. (Italian Trials in Medical Oncology) Group Study

#383

Introduction: Everolimus has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with octreotide.

Aim(s): The primary objective of this multicentric study is to assess the activity and safety of Everolimus + Octreotide LAR as first-line treatment of NETs.

Materials and methods: From March 2009 to June 2010, 50 patients with advanced NETs were treated with Everolimus 10 mg/day and Octreotide LAR 30 mg/month, until disease progression and/or unacceptable toxicity. Forty-two patients had a well-differentiated endocrine carcinoma of the gastrointestinal tract and eight had a typical or atypical lung carcinoid.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Bajetta E, Catena L, Biondani P, Fazio N, Giuffrida D,

Keywords: Everolimus, Octreotide LAR, neuroendocrine tumors,